James JD - Eliem Therapeutics Gen VP
| ELYMDelisted Stock | USD 3.00 0.08 2.60% |
Insider
James JD is Gen VP of Eliem Therapeutics
| Age | 58 |
| Phone | 877 354 3689 |
| Web | https://eliemtx.com |
Eliem Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2454) % which means that it has lost $0.2454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3835) %, meaning that it created substantial loss on money invested by shareholders. Eliem Therapeutics' management efficiency ratios could be used to measure how well Eliem Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| MD MBA | Rezolute | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Robyn Sweinhart | Rezolute | N/A | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| Erin JD | Shattuck Labs | 44 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Jc MD | Adagene | 59 | |
| Osvaldo Flores | Century Therapeutics | 61 | |
| Winston MBA | Pmv Pharmaceuticals | 48 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| , MBA | Molecular Partners AG | 51 | |
| Niels Svenstrup | PepGen | 54 | |
| Dr MBA | MediciNova | 59 | |
| Fatima MD | Shattuck Labs | N/A | |
| Arnold Levine | Pmv Pharmaceuticals | 84 | |
| Deepika PharmD | Pmv Pharmaceuticals | 47 | |
| Conor Richardson | Shattuck Labs | N/A | |
| Jochen Knolle | Pharvaris BV | 74 | |
| Maryann Cimino | Pharvaris BV | N/A | |
Management Performance
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 |
Eliem Therapeutics Leadership Team
Elected by the shareholders, the Eliem Therapeutics' board of directors comprises two types of representatives: Eliem Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eliem. The board's role is to monitor Eliem Therapeutics' management team and ensure that shareholders' interests are well served. Eliem Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eliem Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Lavelle, COO VP | ||
| MD MBA, Chief Officer | ||
| James JD, Gen VP | ||
| Jo PalmerPhillips, Chief Officer | ||
| Andrew MD, Principal Chairman | ||
| Valerie Morisset, Chief Development | ||
| Emily Pimblett, Principal Officer | ||
| BAO BCh, President CEO | ||
| Susan MS, VP Affairs | ||
| Robert MBA, CEO Pres | ||
| MBA MD, Interim Officer | ||
| Nishi MD, Senior Development |
Eliem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eliem Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 122.66 M | |||
| Shares Outstanding | 67.06 M | |||
| Shares Owned By Insiders | 10.38 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 1.15 M | |||
| Price To Book | 1.56 X | |||
| EBITDA | (40.27 M) | |||
| Net Income | (35.12 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |